Pre-surgical targeted molecular therapy in renal cell carcinoma

BJU International

Volumn 103, Issue 2, 2009, Pages 150-153

  Margulis, Vitaly ^a   Wood, Christopher G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Prognostic factors; Renal cell carcinoma; Targeted molecular therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BIOLOGICAL MARKER; INTERLEUKIN 2; SORAFENIB; SUNITINIB;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG WITHDRAWAL; FOLLOW UP; HOSPITALIZATION; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR THERAPY; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SYSTEMIC THERAPY; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY; PROGNOSIS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 58149145722     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08095.x     Document Type: Short Survey

References (29)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 2002 167 : 57 60
3. Wagner JR, Walther MM, Linehan WM et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 1999 162 : 43 5
4. Rackley R, Novick A, Klein E et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994 152 : 1399 403
5. Uzzo RG, Rayman P, Kolenko V et al. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest 1999 104 : 769 76
6. Vieweg J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007 13 : 727s 732s
7. Tatsumi T, Kierstead LS, Ranieri E et al. Disease-associated bias in T helper type 1 (Th1) /Th2 CD4 (+) T cell responses against MAGE-6 in HLA-DRB10401 (+) patients with renal cell carcinoma or melanoma. J Exp Med 2002 196 : 619 28
8. Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001 358 : 966 70
9. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001 345 : 1655 9
10. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004 171 : 1071 6
11. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 34
12. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 349 : 427 34
13. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 24
14. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 356 : 2271 81
15. Walther MM, Alexander RB, Weiss GH et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 1993 42 : 250 7
16. Walther MM, Yang JC, Pass HI et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997 158 : 1675 8
17. Bennett RT, Lerner SE, Taub HC et al. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995 154 : 32 4
18. Bex A, Horenblas S, Meinhardt W et al. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol 2002 42 : 570 4
19. Bex A, Kerst M, Mallo H et al. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur Urol 2006 49 : 76 81
20. van der Veldt AA, Meijerink MR, van den Eertwegh AJ et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 2008 14 : 2431 6
21. Karakiewicz PI, Suardi N, Jeldres C et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008 53 : 845 8
22. Shuch B, Riggs SB, Larochelle JC et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008 102 : 692 6
23. Jonasch E. Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2007 7 : 73 8
24. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2007 13 : 697s 702s
25. Howdieshell TR, Callaway D, Webb WL et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 2001 96 : 173 82
26. Roman CD, Choy H, Nanney L et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002 105 : 43 7
27. Kesmodel SB, Ellis LM, Lin E et al. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases. ASCO Proceedings for Annual Gastrointestinal Cancers Symposium, 2007, 234A
28. Margulis V, Matin SF, Tannir N et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008 180 : 94 8
29. Torigian DA, Huang SS, Houseni M, Alavi A. Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin 2007 57 : 206 24